Baidu
map

J Hepatol:慢性乙型肝炎出现肝脏疾病进展和死亡的危险因素研究

2016-11-10 MedSci MedSci原创

与慢性乙型肝炎(CHB)相关的肝脏疾病进展和死亡率的风险因素知之甚少。 研究纳入CHB出院女患者,多因素Cox比例风险模型,评估肝脏和非肝脏相关危险因素,与肝脏疾病进展(终末期肝病或肝癌)和死亡率的关系。 总体而言,肝脏疾病的进展、肝移植和死亡记录分别有7479 (15.5%)、433 (8.2%)和5299 (11.0%)例。5426 (72.6%)例肝脏疾病进展患者有肝脏相关的危险

与慢性乙型肝炎(CHB)相关的肝脏疾病进展和死亡率的风险因素知之甚少。

研究纳入CHB出院女患者,多因素Cox比例风险模型,评估肝脏和非肝脏相关危险因素,与肝脏疾病进展(终末期肝病或肝癌)和死亡率的关系。

总体而言,肝脏疾病的进展、肝移植和死亡记录分别有7479 (15.5%)、433 (8.2%)和5299 (11.0%)例。5426 (72.6%)例肝脏疾病进展患者有肝脏相关的危险因素记录,2699 (75.5%)例肝移植或肝死亡患者有肝脏相关的危险因素记录。

HDV合并感染、HCV合并感染、酒精使用疾患、糖尿病和其他罕见原因所致慢性肝病,其肝脏疾病进展的校正后HR值分别为1.44 (1.35–1.53)、1.77 (1.68–1.87)、3.37 (3.20–3.55)、1.40 (1.32–1.48)和2.19 (1.98–2.42)。

所有肝相关危险因素增加了死亡率风险,尤其是肝脏疾病进展后。肝脏疾病进展和HIV合并感染但没有AIDS的院内死亡率的校正后HR值分别为0.60 (0.52–0.70)和0.63 (0.51–0.78)。

总的来说,CHB患者的肝脏疾病进展与其他危险因素密切相关。无AIDS的HIV合并感染者有更好的结果,表明这组患者有更好的护理。

原始出处:


Vincent Mallet,Kamal Hamed,Michaël Schwarzinger.Prognosis of Patients with Chronic Hepatitis B in France (2008-2013): A Nationwide, Observational and Hospital-based Study.J Hepatol.Published online: November 5, 2016

本文系梅斯医学(MedSci)原 创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1825604, encodeId=54c118256045a, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 14 05:51:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907664, encodeId=36c1190e6645d, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue May 23 05:51:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253371, encodeId=bba312533e1d8, content=<a href='/topic/show?id=12c98145216' target=_blank style='color:#2F92EE;'>#肝脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81452, encryptionId=12c98145216, topicName=肝脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271242, encodeId=00f212e1242eb, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426682, encodeId=32541426682e1, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1825604, encodeId=54c118256045a, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 14 05:51:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907664, encodeId=36c1190e6645d, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue May 23 05:51:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253371, encodeId=bba312533e1d8, content=<a href='/topic/show?id=12c98145216' target=_blank style='color:#2F92EE;'>#肝脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81452, encryptionId=12c98145216, topicName=肝脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271242, encodeId=00f212e1242eb, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426682, encodeId=32541426682e1, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1825604, encodeId=54c118256045a, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 14 05:51:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907664, encodeId=36c1190e6645d, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue May 23 05:51:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253371, encodeId=bba312533e1d8, content=<a href='/topic/show?id=12c98145216' target=_blank style='color:#2F92EE;'>#肝脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81452, encryptionId=12c98145216, topicName=肝脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271242, encodeId=00f212e1242eb, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426682, encodeId=32541426682e1, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1825604, encodeId=54c118256045a, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 14 05:51:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907664, encodeId=36c1190e6645d, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue May 23 05:51:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253371, encodeId=bba312533e1d8, content=<a href='/topic/show?id=12c98145216' target=_blank style='color:#2F92EE;'>#肝脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81452, encryptionId=12c98145216, topicName=肝脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271242, encodeId=00f212e1242eb, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426682, encodeId=32541426682e1, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1825604, encodeId=54c118256045a, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Mon Aug 14 05:51:00 CST 2017, time=2017-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1907664, encodeId=36c1190e6645d, content=<a href='/topic/show?id=fdcee0731d2' target=_blank style='color:#2F92EE;'>#疾病进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70731, encryptionId=fdcee0731d2, topicName=疾病进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Tue May 23 05:51:00 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1253371, encodeId=bba312533e1d8, content=<a href='/topic/show?id=12c98145216' target=_blank style='color:#2F92EE;'>#肝脏疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81452, encryptionId=12c98145216, topicName=肝脏疾病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87531, createdName=klivis, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271242, encodeId=00f212e1242eb, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1426682, encodeId=32541426682e1, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Sat Nov 12 11:51:00 CST 2016, time=2016-11-12, status=1, ipAttribution=)]
    2016-11-12 gwc384

相关资讯

2013研究荟萃:慢性乙型肝炎免疫研究新进展

目前干扰素和核苷(酸)类似物抗病毒治疗对慢性乙型肝炎(CHB)已取得一定的疗效,然而,目前治疗策略不能有效清除肝细胞核内的共价闭合环状DNA,停药后容易复发。若要达到完全控制或清除乙肝病毒(HBV)感染的目标,则须打破患者免疫耐受,激活机体特异性抗病毒免疫功能,从而获得持久的免疫控制。经过国内外学者多年的深入研究,虽然尚未完全阐明HBV的免疫致病机制,但是通过免疫调节来激活机体抗病毒免疫功能的

NICE全新慢性乙型肝炎诊断和管理指南

  中国工程院医药卫生学部院士,中华医学会肝病学会分会名誉主任委员 庄辉 英国国立优质卫生和保健研究所(National Institute for Health and Care Excellence, NICE)是英国非政府的公共卫生机构,为英格兰和威尔士医疗体系服务,其前身为英国国立优质临床研究所(National Institute for Clinical Excellence

Aliment Pharmacol Ther:抗病毒治疗慢性乙型肝炎,可降低肝癌风险

背景:既往对肝硬化患者的研究表明,进行抗病毒治疗慢性乙型肝炎(CHB),可以降低肝细胞癌(HCC)风险。 目的:本项研究的目标人群定位在伴和不伴肝硬化的CHB患者,探究抗病毒治疗对HCC风险的影响。 方法:研究纳入了2255例CHB患者(来自US队列,973例接受抗病毒治疗)和3653例未接受抗病毒治疗的患者(来自台湾REVEAL-HBV研究)。校正既往已经得到验证的REACH-B风险

《WHO慢性乙型肝炎预防、关怀和治疗指南》中文版发布

2015年5月15日上午,中文版《WHO慢性乙型肝炎预防、关怀和治疗指南》(以下简称为WHO乙肝指南)正式发布。本指南为首个针对慢性乙肝患者进行预防、关怀和治疗的世卫组织指南。指南概览指南建议是按照慢性乙肝患者连续一体关怀体系的结构编写,从初始对疾病分期和治疗指征的评估,开始一线抗病毒治疗,对疾病进展、药物毒性及肝细胞癌发生的监测,到治疗失败时改用二线药物。建议涵盖各年龄段及各种族成人患者。指

临床治愈成为慢性乙型肝炎(CHB)治疗更高目标

    2014年3月1日,旨在讨论慢性乙型肝炎(CHB)患者临床治愈的价值及如何帮助CHB患者获得临床治愈的 研讨会在广州隆重举行。北京大学医学部庄辉院士、复旦大学附属华山医院翁心华教授、北京大学人民医院魏来教授、首都医科大学附属北京友谊医院贾继东教授、 中山大学肝脏病医院高志良教授、南方医院侯金林教授、重庆医科大学附属第二医院任红教授与北京大学第一医院王贵

ILC 2016:NVR 3-778可安全地降低慢性乙型肝炎患者的HBV DNA的水平

据国际肝脏会议上一项新的报道显示,乙型肝炎病毒核心的抑制剂——NVR 3-778,可安全地减少慢性乙型肝炎病毒感染患者的HBV DNA的水平。

Baidu
map
Baidu
map
Baidu
map